Seboldt H
Fortschr Med. 1980 Feb 21;98(7):257-60.
In a double blind placebo-controlled trial the influence of butalamine-hydrochloride (Adrevil forte) in a daily dosage of 3 x 2 tablets on the exercise tolerance of muscles with impaired blood flow in the lower limb was evaluated. The drug was tested versus placebo in a total of 32 patients suffering from peripheral arterial insufficiency stadium II according to Fontaine with occlusions in one or both extremities. Clinical parameters measured were muscle ergometry, plethysmography as well as the assessment of the painfree walking distance. During the whole trial the systemic blood pressure was monitored. The group receiving the active drug showed already after two weeks therapy a statistically significant improvement in the walking distance. After the end of 8 weeks therapy the walking distance in the group under active drug therapy was increased 4 times. Measurements of perfusion also showed significantly higher values under active therapy. The systemic blood pressure was not affected during the 8 weeks therapy with Adrevil forte.
在一项双盲安慰剂对照试验中，评估了每日剂量为3×2片的盐酸布他拉明（Adrevil forte）对下肢血流受损肌肉运动耐量的影响。在总共32例根据Fontaine分级为外周动脉功能不全II期、一侧或双侧肢体有闭塞的患者中，对该药物与安慰剂进行了测试。测量的临床参数包括肌肉测力计检查、体积描记法以及无痛步行距离评估。在整个试验过程中监测了全身血压。接受活性药物治疗的组在治疗两周后步行距离就有统计学上的显著改善。在8周治疗结束后，接受活性药物治疗组的步行距离增加了4倍。灌注测量也显示活性治疗下的值明显更高。在使用Adrevil forte进行8周治疗期间，全身血压未受影响。
